Literature DB >> 25052873

Hepcidin and GDF15 in anemia of multiple myeloma.

Shuchong Mei1, Huaquan Wang, Rong Fu, Wen Qu, Limin Xing, Guojin Wang, Jia Song, Hong Liu, Lijuan Li, Xiaoming Wang, Yuhong Wu, Jin Guan, Erbao Ruan, Zonghong Shao.   

Abstract

Multiple myeloma (MM) is a malignant disease of plasma cells and is often accompanied by anemia which may influence its progression and survival. The mechanism of anemia of chronic disease (ACD) in which iron homeostasis is impaired underlies that of MM-related anemia. In this study, we analyzed the role of hepcidin which is the main mediator of ACD and ACD-related cytokines in peripheral blood of MM patients. We showed that HAMP mRNA and growth differentiation factors 15 (GDF15) mRNA expressions in peripheral blood mononuclear cells (PBMCs) and plasma hepcidin, GDF15, interleukin-6 and erythropoietin in MM patients all increased significantly as compared to those in controls. In MM patients, the expression of HAMP mRNA showed a positive correlation with serum ferritin level, and a negative correlation with hemoglobin level. The levels of plasma hepcidin and GDF15 were significantly decreased in MM patients who achieved complete remission after six cycles VD (bortezomib + dexamethasone) regimen chemotherapy. These data indicated that overexpression of HAMP mRNA in PBMCs significantly correlated with increased plasma hepcidin level and may be involved in the pathogenesis of MM-related anemia. Furthermore, the levels of plasma hepcidin and GDF15 may be valuable in assessing the progress of MM.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25052873     DOI: 10.1007/s12185-014-1626-7

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  30 in total

Review 1.  Erythropoietin and iron-restricted erythropoiesis.

Authors:  Lawrence Tim Goodnough
Journal:  Exp Hematol       Date:  2007-04       Impact factor: 3.084

2.  Mechanism of the cardioprotection of rhEPO pretreatment on suppressing the inflammatory response in ischemia-reperfusion.

Authors:  Xiaoming Liu; Weiying Xie; Pichu Liu; Manlin Duan; Zhen Jia; Wei Li; Jianguo Xu
Journal:  Life Sci       Date:  2005-12-05       Impact factor: 5.037

3.  Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein.

Authors:  Elizabeta Nemeth; Erika V Valore; Mary Territo; Gary Schiller; Alan Lichtenstein; Tomas Ganz
Journal:  Blood       Date:  2002-11-14       Impact factor: 22.113

4.  Serum growth differentiation factor 15 levels in newly diagnosed multiple myeloma patients.

Authors:  Pinar Tarkun; Elif Birtas Atesoglu; Ozgur Mehtap; Mahmut Mert Musul; Abdullah Hacihanefioglu
Journal:  Acta Haematol       Date:  2013-11-09       Impact factor: 2.195

5.  Elevated growth differentiation factor 15 expression in patients with congenital dyserythropoietic anemia type I.

Authors:  Hannah Tamary; Hanna Shalev; Galit Perez-Avraham; Meira Zoldan; Itai Levi; Dorine W Swinkels; Toshihiko Tanno; Jeffery L Miller
Journal:  Blood       Date:  2008-09-29       Impact factor: 22.113

6.  Autocrine formation of hepcidin induces iron retention in human monocytes.

Authors:  Igor Theurl; Milan Theurl; Markus Seifert; Sabine Mair; Manfred Nairz; Holger Rumpold; Heinz Zoller; Rosa Bellmann-Weiler; Harald Niederegger; Heribert Talasz; Günter Weiss
Journal:  Blood       Date:  2007-12-11       Impact factor: 22.113

7.  Different regulatory elements are required for response of hepcidin to interleukin-6 and bone morphogenetic proteins 4 and 9.

Authors:  Jaroslav Truksa; Hongfan Peng; Pauline Lee; Ernest Beutler
Journal:  Br J Haematol       Date:  2007-10       Impact factor: 6.998

Review 8.  Multiple myeloma.

Authors:  Robert A Kyle; S Vincent Rajkumar
Journal:  Blood       Date:  2008-03-15       Impact factor: 22.113

9.  Macrophage inhibitory cytokine MIC-1 is upregulated by short-wavelength light in cultured normal human dermal fibroblasts.

Authors:  Masashi Akiyama; Keiko Okano; Yoshitaka Fukada; Toshiyuki Okano
Journal:  FEBS Lett       Date:  2009-02-10       Impact factor: 4.124

10.  Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European CANCER ANAEMIA SURVEY.

Authors:  Gunnar Birgegård; Pere Gascón; Heinz Ludwig
Journal:  Eur J Haematol       Date:  2006-11       Impact factor: 2.997

View more
  10 in total

Review 1.  Modulation of hepcidin to treat iron deregulation: potential clinical applications.

Authors:  Nicole L Blanchette; David H Manz; Frank M Torti; Suzy V Torti
Journal:  Expert Rev Hematol       Date:  2015-12-15       Impact factor: 2.929

2.  The three isoforms of hepcidin in human serum and their processing determined by liquid chromatography-tandem mass spectrometry (LC-tandem MS).

Authors:  Lynda Addo; Katsuya Ikuta; Hiroki Tanaka; Yasumichi Toki; Mayumi Hatayama; Masayo Yamamoto; Satoshi Ito; Motohiro Shindo; Yusuke Sasaki; Yasushi Shimonaka; Mikihiro Fujiya; Yutaka Kohgo
Journal:  Int J Hematol       Date:  2016-01       Impact factor: 2.490

Review 3.  Iron and cancer: recent insights.

Authors:  David H Manz; Nicole L Blanchette; Bibbin T Paul; Frank M Torti; Suzy V Torti
Journal:  Ann N Y Acad Sci       Date:  2016-02-18       Impact factor: 5.691

Review 4.  The relationship between systemic iron homeostasis and erythropoiesis.

Authors:  Gautam Rishi; V Nathan Subramaniam
Journal:  Biosci Rep       Date:  2017-11-29       Impact factor: 3.840

5.  Associations Between Cardiac Biomarkers and Cardiac Structure and Function in CKD.

Authors:  Nathan R Stein; Leila R Zelnick; Amanda H Anderson; Robert H Christenson; Christopher R deFilippi; Rajat Deo; Alan S Go; Jiang He; Bonnie Ky; James P Lash; Stephen L Seliger; Elsayed Z Soliman; Michael G Shlipak; Nisha Bansal
Journal:  Kidney Int Rep       Date:  2020-05-07

Review 6.  New Biomarkers of Ferric Management in Multiple Myeloma and Kidney Disease-Associated Anemia.

Authors:  Małgorzata Banaszkiewicz; Jolanta Małyszko; David H Vesole; Karolina Woziwodzka; Artur Jurczyszyn; Marcin Żórawski; Marcin Krzanowski; Jacek Małyszko; Krzysztof Batko; Marek Kuźniewski; Katarzyna Krzanowska
Journal:  J Clin Med       Date:  2019-11-01       Impact factor: 4.241

Review 7.  Anaemia of Chronic Disease: An In-Depth Review.

Authors:  Anazoeze Jude Madu; Maduka Donatus Ughasoro
Journal:  Med Princ Pract       Date:  2016-09-28       Impact factor: 1.927

Review 8.  Limitations of Serum Ferritin in Diagnosing Iron Deficiency in Inflammatory Conditions.

Authors:  Axel Dignass; Karima Farrag; Jürgen Stein
Journal:  Int J Chronic Dis       Date:  2018-03-18

9.  Hepcidin and GDF-15 are potential biomarkers of iron deficiency anaemia in chronic kidney disease patients in South Africa.

Authors:  Aishatu M Nalado; Gbenga Olorunfemi; Therese Dix-Peek; Caroline Dickens; Lungile Khambule; Tracy Snyman; Graham Paget; Johnny Mahlangu; Raquel Duarte; Jaya George; Saraladevi Naicker
Journal:  BMC Nephrol       Date:  2020-09-29       Impact factor: 2.388

10.  The Key Role of Hepcidin-25 in Anemia in Multiple Myeloma Patients with Renal Impairment.

Authors:  Małgorzata Banaszkiewicz; Jolanta Małyszko; Krzysztof Batko; Ewa Koc-Żórawska; Marcin Żórawski; Paulina Dumnicka; Artur Jurczyszyn; Karolina Woziwodzka; Aleksandra Maleszka; Marcin Krzanowski; Andrzej Kraśniak; Ryszard Drożdż; Katarzyna Krzanowska
Journal:  Medicina (Kaunas)       Date:  2022-03-11       Impact factor: 2.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.